US6284284B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions and methods for production and use of an injectable naturally secreted extracellular matrix
Assignee: Organogenesis Inc
•
Filing: 1998-10-29
•
Granted: 2001-09-04
•
Expires: 2018-10-29
Abstract
Abstract The present invention discloses compositions containing natural human extracellular matrices and methods for the use thereof. More particularly, the present invention provides compositions and methods for the repair of skin defects using natural human extracellular matrix by injection.
Inventors
- 👤 Gail K. Naughton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 01:50
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/3604; A61L27/3633; A61L27/3683; A61L27/38; A61L27/3804; A61L27/3839; A61L27/50; A61L27/60; A61Q; A61Q19/00; A61Q19/08; A61F; A61F2/00; A61F2/0059; A61F2/02; A61F2/10; A61F2/105; Y; Y10; Y10T; Y10T442/00; Y10T442/20; Y10T442/2525
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
55 words
A method for the repair of a skin defect comprising: injecting a human secreted extracellular matrix comprising a mixture of cell-free, naturally secreted human extracellular components derived from living stromal tissue formulated for in vivo administration by injection via a syringe and a pharmaceutically acceptable carrier at a site of a skin or tissue defect.
Claim 2
Independent Claim
55 words
A method for the repair of a skin defect comprising: injecting a human secreted extracellular matrix comprising a mixture of cell-free, naturally secreted human extracellular components derived from living stromal tissue formulated for in vivo administration by injection via a syringe and a pharmaceutically acceptable carrier at a site of a skin or tissue defect.
Claim 3
Dependent Claim
138 words
The method according to claim 1 in which the naturally secreted extracellular matrix is produced by a method comprising: (a) providing a living stromal tissue prepared in vitro comprising human stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework, said framework composed of a biocompatible, non-living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells; (b) killing the cells in the living stromal tissue; (c) removing the killed cells and any cellular contents from the framework; (d) collecting the connective tissue proteins naturally secreted by the stromal cells attached to the framework; and (e) processing the collected connective tissue proteins of step (d) with a pharmaceutically acceptable carrier into a formulation that is suitable for in vivo administration by injection via a syringe.
Claim 4
Dependent Claim
37 words
The method according to claim 2 in which the collected connective tissue proteins of step (d) are processed by homogenizing, cross-linking, or suspending the collected connective tissue proteins in a physiological acceptable carrier prior to step (e).
Claim 5
Dependent Claim
33 words
The method according to claim 2 in which the collected connective tissue proteins of step (d) are processed by adjusting ratios of collagen types I-V, respective to each other, prior to step (e).
Claim 6
Dependent Claim
18 words
The method according to claim 2 in which the stromal cells of the living stromal tissue are fibroblasts.
Claim 7
Dependent Claim
26 words
The method according to claim 2 in which the stromal cells of the living stromal tissue are cells found in loose connective tissue or bone marrow.
Claim 8
Dependent Claim
30 words
The method according to claim 6 in which the stromal cells of the living stromal tissue are endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells, chondrocytes or adipocytes.
Claim 9
Dependent Claim
16 words
The method according to claim 2 in which the framework is composed of a biodegradable material.
Claim 10
Dependent Claim
22 words
The method according to claim 8 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.
Claim 11
Dependent Claim
16 words
The method according to claim 2 in which the framework is composed of a non-biodegradable material.
Claim 12
Dependent Claim
32 words
The method according to claim 10 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluoroethylene, or a nitrocellulose compound.
Claim 13
Dependent Claim
31 words
The method according to claim 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 or 11 in which the framework is a mesh.
Claim 14
Dependent Claim
21 words
The method according to claim 12 in which the framework has pore spaces of about 150 μm to about 220 μm.
Claim 15
Dependent Claim
26 words
The method according to claim 2 in which the pharmaceutically acceptable carrier contains an anesthetic agent, a lubricating agent, a tissue growth factor or combinations thereof.
Claim 16
Dependent Claim
131 words
The method according to claim 1 in which the naturally secreted extracellular matrix is produced by a method comprising: (a) providing a living stromal tissue prepared in vitro comprising human stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework, said framework composed of a biocompatible, non-living biodegradable material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells; (b) killing the cells in the living stromal tissue; (c) removing the killed cells and any cellular contents from the framework; and (d) processing the connective tissue proteins naturally secreted by the stromal cells attached to the framework and the biodegradable framework with a pharmaceutically acceptable carrier into a formulation suitable for in vivo administration by injection via a syringe.
Claim 17
Dependent Claim
38 words
The method according to claim 6 in which the stromal cells of the living stromal tissue are glial cells, liver cells, hematopoietic cells, dermal cells, lens fiber cells, smooth muscle cells, osteoblast cells, odontoblast cells, or retinal cells.
References Cited (Backward Citations)
US3949073A
Cited
US4424208A
Cited
US4582640A
Cited
US4801299A
Cited
US4837285A
Cited
US5288617A
Cited
US5460939A
Cited
US5443950A
Cited
US5160490A
Cited
US4721096A
Cited
US5266480A
Cited
US4803075A
Cited
US5002071A
Cited
US4963489A
Cited
US5032508A
Cited
EP0466105A2
Cited
US5342765A
Cited
US5204382A
Cited
US5478739A
Cited
US5541106A
Cited
US5397352A
Cited
US5716394A
Cited
WO1995031944A1
Cited
US5516532A
Cited
WO1996008213A1
Cited
WO1996039101A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-09-03 | 2005-03-05 | 2005-09-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-09-03 | 2009-03-05 | 2009-09-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-09-03 | 2013-03-05 | 2013-09-04 | $7700.00 | Window Closed / Lapsed |